Home    Back

Gentamicin    (DrugBank: Gentamicin)

3 diseases
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa7
113Muscular dystrophy2
299Cystic fibrosis1

36. Epidermolysis bullosa    [ 147 clinical trials,   170 drugs,   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways]
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 147 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04644627
(ClinicalTrials.gov)		December 1, 202020/11/2020Topical Gentamicin Nonsense Suppression Therapy of EBTOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONSEpidermolysis BullosaDrug: Gentamicin SulfateOslo University HospitalNULLNot yet recruitingN/AN/AAll6Phase 1;Phase 2Norway
2EUCTR2020-002337-15-NO
(EUCTR)		16/09/202029/06/2020TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSATOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS (THE GENTELBULL STUDY) - GENTELBULL Epidermolysis bullosa caused by nonsense mutations or splice site mutations;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Trade Name: Infectogenta
Product Name: Gentamicin sulfate 0.1% ointment		Oslo University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		6Phase 2Norway
3NCT04140786
(ClinicalTrials.gov)		October 31, 201923/10/2019Optimizing IV Gentamicin in JEBOptimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients With Nonsense MutationsJunctional Epidermolysis BullosaDrug: Gentamicin Sulfate, InjectableUniversity of Southern CaliforniaNULLRecruitingN/AN/AAll6Phase 1;Phase 2United States
4NCT03392909
(ClinicalTrials.gov)		July 5, 20182/1/2018Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)Restoration of Full-Length Type VII Collagen in RDEB Patients With Nonsense Mutations After Intravenous Gentamicin TreatmentRecessive Dystrophic Epidermolysis BullosaDrug: GentamicinUniversity of Southern CaliforniaNULLRecruiting7 YearsN/AAll9Phase 1;Phase 2United States
5NCT03526159
(ClinicalTrials.gov)		June 1, 201817/4/2018Gentamicin for Junctional Epidermolysis BullosaA Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin TreatmentJunctional Epidermolysis BullosaDrug: Gentamicin SulfateUniversity of Southern CaliforniaNULLRecruitingN/AN/AAll6Phase 1;Phase 2United States
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT03012191
(ClinicalTrials.gov)		February 2, 20174/1/2017Gentamicin for RDEBGentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense MutationsRecessive Dystrophic Epidermolysis BullosaDrug: Gentamicin SulfateUniversity of Southern CaliforniaNULLCompletedN/AN/AAll6Phase 1;Phase 2United States
7NCT02698735
(ClinicalTrials.gov)		February 25, 201619/2/2016Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation PatientsRecessive Dystrophic Epidermolysis BullosaDrug: Gentamicin;Drug: PlaceboUniversity of Southern CaliforniaNULLCompletedN/AN/AAll5Phase 1;Phase 2NULL

Back to top


113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 567 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00451074
(ClinicalTrials.gov)		March 200721/3/2007Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop CodonsA Six Month Randomized, Clinical Trial of Gentamicin in Duchenne Muscular Dystrophy Subjects With Stop Codon MutationsDuchenne Muscular DystrophyDrug: Gentamicin infusions twice a week for six monthsNationwide Children's HospitalNational Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)Completed5 Years20 YearsMale12Phase 1United States
2NCT00005574
(ClinicalTrials.gov)		February 20002/5/2000Gentamicin Treatment of Muscular DystrophyGentamicin Treatment of Patients With Muscular Dystrophy Due to Nonsense Mutations in DystrophinBecker Muscular Dystrophy;Duchenne Muscular DystrophyDrug: GentamicinNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth4Phase 1United States

299. Cystic fibrosis    [ 1,592 clinical trials,   1,539 drugs,   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways]
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1,592 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00376428
(ClinicalTrials.gov)		January 200313/9/2006Interest of Gentamicin-induced Readthrough in Cystic Fibrosis PatientsApplication of Functional Electrophysiological Tests to Evaluate Pharmacological Treatments in Patients With Cystic FibrosisCystic FibrosisDrug: GentamicinAssistance Publique - Hôpitaux de ParisNULLTerminatedN/AN/ABoth20Phase 2France

Back to top